for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Solid Biosciences Inc

SLDB.O

Latest Trade

2.55USD

Change

-0.15(-5.56%)

Volume

118,731

Today's Range

2.51

 - 

2.73

52 Week Range

1.96

 - 

13.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Solid Biosciences Announces Appointment Of Ian F. Smith As Chairman Of The Board Of Directors

* SOLID BIOSCIENCES ANNOUNCES APPOINTMENT OF IAN F. SMITH AS CHAIRMAN OF THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Solid Biosciences Says Board Appointed Ian Smith As Chairman

* SOLID BIOSCIENCES - ON JUNE 16, BOARD APPOINTED IAN SMITH AS CHAIRMAN - SEC FILING

BRIEF-Solid Biosciences Announces Appointment Of Ian F. Smith To Its Board

* SOLID BIOSCIENCES ANNOUNCES APPOINTMENT OF IAN F. SMITH TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Solid Biosciences Reports Q4 & Full Year 2019 Financial Results

* SOLID BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

UPDATE 1-Solid Biosciences medicines chief to step down, to cut workforce by one third

Solid Biosciences Inc said on Thursday its head of medicines would step down and that it would layoff one third of its workforce as the drug developer works to bring an end to the clinical halt on a trial of its experimental gene therapy.

Solid Biosciences to cut workforce, focus on DMD gene therapy

Solid Biosciences Inc said on Thursday it would cut its workforce by about one third and focus on its experimental gene therapy for muscle-wasting disorder Duchenne muscular dystrophy (DMD), after a trial of the treatment was halted in November.

Solid Biosciences shares plummet as gene therapy trial halted again

Shares in Solid Biosciences Inc plunged 71% on Tuesday after a trial testing its gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

Solid Biosciences gene therapy trial put on hold by FDA

Solid Biosciences Inc said on Tuesday the U.S. Food and Drug Administration has put on hold a trial testing its gene therapy for a muscle-wasting disorder.

BRIEF-Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING Source text: (https://bit.ly/2GwS8zg) Further company coverage:

BRIEF-Solid Biosciences Reports Quarterly Loss Per Share Of $0.54

* SOLID BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Solid Biosciences Reports Full Year 2017 Financial Results And Provides Corporate Update

* SOLID BIOSCIENCES REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial

* SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing

* SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up